Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.24.64 (
MPP
)
1,876
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Neurodegenerative diseases are complex multifactorial disorders characterised by the interplay of many dysregulated physiological processes. As an exemplar, Parkinson's disease (PD) involves multiple perturbed cellular functions, including mitochondrial dysfunction and autophagic dysregulation in preferentially-sensitive dopamine neurons, a selective pathophysiology recapitulated in vitro using the neurotoxin
MPP
(+). Here we explore a network science approach for the selection of therapeutic protein targets in the cellular
MPP
(+) model. We hypothesised that analysis of protein-protein interaction networks modelling
MPP
(+) toxicity could identify proteins critical for mediating
MPP
(+) toxicity. Analysis of protein-protein interaction networks constructed to model the interplay of mitochondrial dysfunction and autophagic dysregulation (key aspects of
MPP
(+) toxicity) enabled us to identify four proteins predicted to be key for
MPP
(+) toxicity (P62,
GABARAP
, GBRL1 and GBRL2). Combined, but not individual, knockdown of these proteins increased cellular susceptibility to
MPP
(+) toxicity. Conversely, combined, but not individual, over-expression of the network targets provided rescue of
MPP
(+) toxicity associated with the formation of autophagosome-like structures. We also found that modulation of two distinct proteins in the protein-protein interaction network was necessary and sufficient to mitigate neurotoxicity. Together, these findings validate our network science approach to multi-target identification in complex neurological diseases.
...
PMID:Protein-protein interaction networks identify targets which rescue the MPP+ cellular model of Parkinson's disease. 2660 97